ABIVAX Société Anonyme (ABVX) Competitors $7.12 0.00 (0.00%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVX vs. AGIO, CGON, ANIP, APGE, IMCR, KNSA, IRON, SPRY, EWTX, and VERAShould you be buying ABIVAX Société Anonyme stock or one of its competitors? The main competitors of ABIVAX Société Anonyme include Agios Pharmaceuticals (AGIO), CG Oncology (CGON), ANI Pharmaceuticals (ANIP), Apogee Therapeutics (APGE), Immunocore (IMCR), Kiniksa Pharmaceuticals (KNSA), Disc Medicine (IRON), ARS Pharmaceuticals (SPRY), Edgewise Therapeutics (EWTX), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry. ABIVAX Société Anonyme vs. Agios Pharmaceuticals CG Oncology ANI Pharmaceuticals Apogee Therapeutics Immunocore Kiniksa Pharmaceuticals Disc Medicine ARS Pharmaceuticals Edgewise Therapeutics Vera Therapeutics Agios Pharmaceuticals (NASDAQ:AGIO) and ABIVAX Société Anonyme (NASDAQ:ABVX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk. Does the media prefer AGIO or ABVX? In the previous week, Agios Pharmaceuticals had 4 more articles in the media than ABIVAX Société Anonyme. MarketBeat recorded 10 mentions for Agios Pharmaceuticals and 6 mentions for ABIVAX Société Anonyme. Agios Pharmaceuticals' average media sentiment score of 1.05 beat ABIVAX Société Anonyme's score of 0.94 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ABIVAX Société Anonyme 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, AGIO or ABVX? Agios Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, ABIVAX Société Anonyme has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Do analysts recommend AGIO or ABVX? Agios Pharmaceuticals currently has a consensus price target of $56.57, suggesting a potential upside of 90.54%. ABIVAX Société Anonyme has a consensus price target of $34.00, suggesting a potential upside of 377.53%. Given ABIVAX Société Anonyme's stronger consensus rating and higher possible upside, analysts clearly believe ABIVAX Société Anonyme is more favorable than Agios Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agios Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56ABIVAX Société Anonyme 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, AGIO or ABVX? Agios Pharmaceuticals has higher revenue and earnings than ABIVAX Société Anonyme. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgios Pharmaceuticals$36.50M46.61$673.72M$11.342.62ABIVAX Société AnonymeN/AN/A-$159.90MN/AN/A Does the MarketBeat Community prefer AGIO or ABVX? Agios Pharmaceuticals received 481 more outperform votes than ABIVAX Société Anonyme when rated by MarketBeat users. However, 76.92% of users gave ABIVAX Société Anonyme an outperform vote while only 66.98% of users gave Agios Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAgios PharmaceuticalsOutperform Votes49166.98% Underperform Votes24233.02% ABIVAX Société AnonymeOutperform Votes1076.92% Underperform Votes323.08% Do insiders and institutionals have more ownership in AGIO or ABVX? 47.9% of ABIVAX Société Anonyme shares are owned by institutional investors. 4.9% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is AGIO or ABVX more profitable? Agios Pharmaceuticals has a net margin of 1,845.92% compared to ABIVAX Société Anonyme's net margin of 0.00%. ABIVAX Société Anonyme's return on equity of 0.00% beat Agios Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Agios Pharmaceuticals1,845.92% -2.51% -2.26% ABIVAX Société Anonyme N/A N/A N/A SummaryAgios Pharmaceuticals beats ABIVAX Société Anonyme on 9 of the 16 factors compared between the two stocks. Get ABIVAX Société Anonyme News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVX vs. The Competition Export to ExcelMetricABIVAX Société AnonymePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$451.54M$6.89B$5.57B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.4422.4418.48Price / SalesN/A242.70394.09103.59Price / CashN/A65.8538.1834.62Price / Book2.116.516.774.25Net Income-$159.90M$143.21M$3.22B$248.23M7 Day Performance2.74%1.98%1.49%0.89%1 Month Performance20.88%6.89%4.00%3.53%1 Year Performance-52.66%-2.52%16.21%5.08% ABIVAX Société Anonyme Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVXABIVAX Société Anonyme2.2258 of 5 stars$7.12flat$34.00+377.5%-52.5%$451.54MN/A0.0061Analyst ForecastNews CoverageGap UpAGIOAgios Pharmaceuticals4.3137 of 5 stars$27.34-1.2%$56.57+106.9%-8.6%$1.57B$36.50M2.41390Upcoming EarningsNews CoveragePositive NewsCGONCG Oncology2.0957 of 5 stars$20.41-1.1%$59.33+190.7%-33.0%$1.56B$1.14M-14.3761Upcoming EarningsAnalyst ForecastNews CoverageANIPANI Pharmaceuticals4.3469 of 5 stars$68.00-1.7%$80.13+17.8%+7.3%$1.51B$614.38M-123.64600APGEApogee Therapeutics2.2181 of 5 stars$32.85-0.8%$92.17+180.6%-22.0%$1.48BN/A-13.5791Positive NewsGap DownIMCRImmunocore3.0457 of 5 stars$29.41+3.5%$63.73+116.7%-49.1%$1.47B$310.20M-30.96320Upcoming EarningsPositive NewsKNSAKiniksa Pharmaceuticals2.4823 of 5 stars$20.05-0.8%$37.17+85.4%+44.1%$1.46B$423.24M-143.20220Earnings ReportAnalyst ForecastNews CoverageIRONDisc Medicine2.3669 of 5 stars$42.06-0.3%$93.80+123.0%+77.5%$1.45BN/A-10.5730Upcoming EarningsNews CoveragePositive NewsSPRYARS Pharmaceuticals3.118 of 5 stars$14.32-3.8%$31.00+116.5%+60.6%$1.41B$89.15M-28.0890Upcoming EarningsNews CoveragePositive NewsHigh Trading VolumeEWTXEdgewise Therapeutics3.2347 of 5 stars$13.30-1.1%$40.13+201.7%-8.6%$1.39BN/A-8.8760Upcoming EarningsAnalyst ForecastShort Interest ↑Positive NewsVERAVera Therapeutics2.9478 of 5 stars$21.11-0.8%$64.67+206.3%-40.9%$1.35BN/A-8.0940Upcoming EarningsNews CoveragePositive NewsGap Down Related Companies and Tools Related Companies AGIO Competitors CGON Competitors ANIP Competitors APGE Competitors IMCR Competitors KNSA Competitors IRON Competitors SPRY Competitors EWTX Competitors VERA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABVX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABIVAX Société Anonyme Please log in to your account or sign up in order to add this asset to your watchlist. Share ABIVAX Société Anonyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ABVX Stock Free ABVX Stock Alerts